Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 14/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.41 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.41 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.41 |
| ▸ | DUSP22 | Q9NRW4 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13746324 | 0.91 | KDR (0.44) | KDRPTPN11MAOB | |
| SCHEMBL13745703 | 0.91 | KDR (0.38) | KDRPTPN11PTPRCPTPN2PTPN1 | |
| SCHEMBL13746204 | 0.88 | KDR (0.41) | KDRPTPN11MAOBKMT2A | |
| SCHEMBL13745686 | 0.87 | KDR (0.35) | KDRPTPN11 | |
| SCHEMBL13745729 | 0.86 | GSK3B (0.36) | KDRPTPN11 | |
| SCHEMBL13745730 | 0.85 | MAOB (0.39) | KDRMAOB | |
| SCHEMBL13746292 | 0.83 | GSK3B (0.34) | PTPN11KMT2A | |
| SCHEMBL13745666 | 0.81 | KDR (0.40) | KDRPTPN11MAOB | |
| SCHEMBL13745690 | 0.81 | GSK3B (0.34) | — | |
| SCHEMBL13745726 | 0.80 | BRD4 (0.37) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | KDR 3757/4885PTPN11 1694/4885MAOB 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.